Tower Research Capital (TRC)’s CoLucid Pharmaceuticals CLCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
– Sell
-1,571
Closed -$57K – 4560
2016
Q4
$57K Buy
+1,571
New +$55.6K 0.01% 1353
2016
Q2
– Sell
-1,339
Closed -$8K – 5413
2016
Q1
$8K Buy
1,339
+539
+67% +$3.37K ﹤0.01% 2299
2015
Q4
$7K Sell
800
-10,755
-93% -$56.6K ﹤0.01% 2685
2015
Q3
$45K Buy
+11,555
New +$85.4K ﹤0.01% 1106

Other funds holding CLCD

Tower Research Capital (TRC)'s CLCD Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of CoLucid Pharmaceuticals (CLCD) in Q1 2017, closing a stake of 1,571 shares — an estimated $57K sold.

Tower Research Capital (TRC) first reported a position in CLCD in Q3 2015 and held it in 4 quarters. The position peaked at $57K in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

  • Tower Research Capital (TRC) reported no remaining CoLucid Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,571 CoLucid Pharmaceuticals shares in Q1 2017, an estimated $57K.
  • Tower Research Capital (TRC) first reported a position in CoLucid Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Tower Research Capital (TRC)'s CoLucid Pharmaceuticals position peaked at $57K in Q4 2016.
  • 1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.